about
P-glycoprotein (ABCB1) but not multidrug resistance-associated protein 1 (ABCC1) is induced by doxorubicin in primary cultures of rat astrocytesInduction of P-glycoprotein and Bcrp at the rat blood-brain barrier following a subchronic morphine treatment is mediated through NMDA/COX-2 activationExpression and function of multidrug resistance transporters at the blood-brain barriers.CNS delivery via adsorptive transcytosis.Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats[¹¹C]befloxatone brain kinetics is not influenced by Bcrp function at the blood-brain barrier: a PET study using Bcrp TGEM knockout rats.Neuropharmacokinetics of a new alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) modulator, S18986 [(S)-2,3-dihydro-[3,4]cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide], in the rat.Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats.Peptide delivery to the brain via adsorptive-mediated endocytosis: advances with SynB vectors.Aryl hydrocarbon receptor-dependent upregulation of Cyp1b1 by TCDD and diesel exhaust particles in rat brain microvesselsInfluence of P-Glycoprotein Inhibition or Deficiency at the Blood-Brain Barrier on (18)F-2-Fluoro-2-Deoxy-D-glucose ( (18)F-FDG) Brain KineticsPeptide vectors as drug carriers.Heterogeneity in the rat brain vasculature revealed by quantitative confocal analysis of endothelial barrier antigen and P-glycoprotein expression.Pharmacophore-based discovery of inhibitors of a novel drug/proton antiporter in human brain endothelial hCMEC/D3 cell lineTransport of biogenic amine neurotransmitters at the mouse blood-retina and blood-brain barriers by uptake1 and uptake2Targeted unlabeled multiple reaction monitoring analysis of cell markers for the study of sample heterogeneity in isolated rat brain cortical microvessels.Role of ABC transporters in the chemoresistance of human gliomas.Colchicine today.Design of cocaethylene and cocaine conjugates to produce highly selective polyclonal antibodies.Coexistence of passive and proton antiporter-mediated processes in nicotine transport at the mouse blood-brain barrier.Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approachEffects of selected OATP and/or ABC transporter inhibitors on the brain and whole-body distribution of glyburide.Pharmacology of morphine in obese patients: clinical implications.Transporters in absorption, distribution, and elimination.ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders.Interplay of drug metabolizing CYP450 enzymes and ABC transporters in the blood-brain barrier.Opioid transport by ATP-binding cassette transporters at the blood-brain barrier: implications for neuropsychopharmacology.Hurdles with using in vitro models to predict human blood-brain barrier drug permeability: a special focus on transporters and metabolizing enzymes.Human ABC transporters at blood-CNS interfaces as determinants of CNS drug penetration.Methodologies to assess drug permeation through the blood-brain barrier for pharmaceutical research.Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells.Effect of Long-term In Vitro Lithium Exposure on mRNA Levels of Claudin-3, CYP1A1, ABCG2 and GSTM3 Genes in the hCMEC/D3 Human Brain Endothelial Cell Line.Aryl hydrocarbon receptor regulates CYP1B1 but not ABCB1 and ABCG2 in hCMEC/D3 human cerebral microvascular endothelial cells after TCDD exposure.Carrier-mediated cocaine transport at the blood-brain barrier as a putative mechanism in addiction liability.Hypoxia interferes with aryl hydrocarbon receptor pathway in hCMEC/D3 human cerebral microvascular endothelial cells.A physiologically based modeling strategy during preclinical CNS drug development.Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood-brain barrier model.Expression and induction by dexamethasone of ABC transporters and nuclear receptors in a human T-lymphocyte cell line.ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier.
P50
Q28572696-AF4054AB-8F4D-40B9-9884-68946BA149ABQ28578377-19AE8038-C3EF-4DDB-B110-4566F28D0EB7Q33998841-F4AE0EA8-42CB-4562-A300-B360C98C3549Q34013526-71296016-A4BA-4457-9492-69148EB75B92Q34128875-894D8703-9E44-408F-B9D7-5A10BD7CDF99Q34367014-76EAC437-AA31-4CCB-B981-32053B596096Q34414670-ADB986AA-1DB6-4B16-AB4B-74218BB00E23Q35045144-E898B81A-CFB5-4927-830B-D12C97879131Q35088660-C4AC3FDE-CAF9-40AA-B813-853CA1C3A6C6Q35232729-B8F68C39-604E-4B3A-BF53-386150270ADCQ35529180-45FF9FB6-6259-4474-A5FF-4AA8C0A7882FQ35607503-17623321-D400-4678-9879-F8E385168D65Q35880855-B84BD03A-DD4A-41A1-8138-729A74280198Q36211219-ACD68BFB-8430-4205-8AC0-A7CA7A4C28A3Q36386144-5DA62DA1-D5F3-413E-A58F-48F4BDCCC76BQ36392766-CED9B723-138A-4813-BEA3-4CAC843EEDE5Q36569855-F04F90FD-031B-4078-BA7D-D8AD7C7F0D37Q36635754-59CC5BBA-B58A-4C75-B880-38DD9E7B604AQ36735069-ECA07592-3B9D-4F51-AAFC-5DA8E4CBAD39Q36910582-42DB24E3-085A-49AC-96CD-06F846EF719AQ37207750-7835040C-4890-4569-9C91-EAE22F4E980DQ37207803-7424B252-7E30-4433-AEA8-B5F82F04E850Q37594760-7C6CCCB6-2A66-4720-A7A1-C86964BD0D37Q37638521-548EC0CF-557B-4249-8DD1-DCD686E35E12Q37789041-E8D7D675-DC23-413D-873B-59D9371A6504Q37881974-30D22DF3-689A-4E6C-9871-B482FB90541FQ37914239-CCE477D9-D605-4FC7-A34E-B5AB21EC7FE6Q38065213-94DC6BC5-8F4C-496F-AB48-0671D19284AEQ38116076-FF2E9746-2808-4FA9-82C7-41D7B884A8B1Q38117056-B8419F86-2716-4F02-94AC-35563841D160Q38295848-9889A8C3-1519-4695-A477-8227B49C3836Q38358564-E6E5E04B-FFB8-4731-AAAD-D2744252339DQ38709323-1FF345B3-02C2-46D5-A3BB-2DE7BF0A868FQ38889077-57BF3E8A-6420-48CE-A59F-4A35F0002320Q38925591-A7801B29-D3C3-40A5-9A27-9D647033B894Q38946707-239E9AE0-F61E-4D3E-9545-196C9827FCF1Q39032437-7C7A92AA-25B0-4D3D-A592-4FC909BA485CQ39247733-C7AC8CFD-7295-4ED5-9B96-7E00F6EAB2A1Q39356163-181038A5-E2A4-4F5C-959B-6BB19F987FD8Q39385313-89DF5591-9500-4C15-A35E-A60909717CFF
P50
name
Jean-Michel Scherrmann
@en
Jean-Michel Scherrmann
@nl
type
label
Jean-Michel Scherrmann
@en
Jean-Michel Scherrmann
@nl
prefLabel
Jean-Michel Scherrmann
@en
Jean-Michel Scherrmann
@nl